Abbott Third-Quarter Profit Tops Estimates as Generic Sales Rise

Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, reported third-quarter earnings that topped analysts’ estimates as sales of its generic drugs rose in emerging markets.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.